• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome - time is of the essence.

作者信息

Teoh Narci, Farrell Geoff

机构信息

Gastroenterology and Hepatology Unit, Medicine and Surgery Program, The Australian National University, Canberra, Australian Capital Territory, Australia.

出版信息

J Clin Transl Res. 2020 Apr 18;5(5):227-229. eCollection 2020 Jun 9.

PMID:32617428
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7326274/
Abstract
摘要

相似文献

1
Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome - time is of the essence.他汀类药物作为减轻新型冠状病毒肺炎（SARS-CoV-2）相关急性呼吸窘迫综合征和细胞因子风暴综合征的早期治疗——时间至关重要。
J Clin Transl Res. 2020 Apr 18;5(5):227-229. eCollection 2020 Jun 9.
2
Innate Receptor Activation Patterns Involving TLR and NLR Synergisms in COVID-19, ALI/ARDS and Sepsis Cytokine Storms: A Review and Model Making Novel Predictions and Therapeutic Suggestions.固有受体激活模式涉及 COVID-19、ALI/ARDS 和脓毒症细胞因子风暴中的 TLR 和 NLR 协同作用：综述和模型制作新的预测和治疗建议。
Int J Mol Sci. 2021 Feb 20;22(4):2108. doi: 10.3390/ijms22042108.
3
Statins and Covid-19: The Neglected Front of bidirectional effects.他汀类药物与新冠病毒：双向作用被忽视的前沿。
J Pak Med Assoc. 2021 Dec;71(Suppl 8)(12):S133-S136.
4
Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality.中性粒细胞胞外陷阱 (NETs) 与新冠病毒 2019 (Covid-19)：治疗模式的新前沿。
Int Immunopharmacol. 2022 Mar;104:108516. doi: 10.1016/j.intimp.2021.108516. Epub 2022 Jan 6.
5
Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome.血红素加氧酶-1（HO-1）细胞保护途径：一种针对 2019 年冠状病毒病（COVID-19）诱导的细胞因子风暴综合征的潜在治疗策略。
Med Hypotheses. 2020 Nov;144:110242. doi: 10.1016/j.mehy.2020.110242. Epub 2020 Sep 3.
6
Repurposing of drugs targeting the cytokine storm induced by SARS-CoV-2.针对由 SARS-CoV-2 引起的细胞因子风暴的药物再利用。
Br J Pharmacol. 2023 Jan;180(2):133-143. doi: 10.1111/bph.15987. Epub 2022 Nov 30.
7
Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients.托珠单抗治疗 COVID-19 急性呼吸窘迫综合征：两例危重症患者的成功转归。
Immunotherapy. 2020 Oct;12(15):1127-1132. doi: 10.2217/imt-2020-0154. Epub 2020 Jul 14.
8
Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.托珠单抗治疗重症新型冠状病毒肺炎减轻细胞因子风暴并避免急性呼吸窘迫期间机械通气：病例报告及文献综述
Trop Med Infect Dis. 2020 Jul 3;5(3):112. doi: 10.3390/tropicalmed5030112.
9
Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis.细胞因子风暴和I型干扰素反应在新冠病毒疾病发病机制中的关键决定因素
Clin Microbiol Rev. 2021 May 12;34(3). doi: 10.1128/CMR.00299-20. Print 2021 Jun 16.
10
Δ9-Tetrahydrocannabinol Prevents Mortality from Acute Respiratory Distress Syndrome through the Induction of Apoptosis in Immune Cells, Leading to Cytokine Storm Suppression.Δ9-四氢大麻酚通过诱导免疫细胞凋亡，从而抑制细胞因子风暴，防止急性呼吸窘迫综合征导致的死亡。
Int J Mol Sci. 2020 Aug 28;21(17):6244. doi: 10.3390/ijms21176244.

引用本文的文献

1
Effects of different antiplatelet therapy drugs on platelet activation and platelet-leukocyte aggregate formation in early septic ARDS.不同抗血小板治疗药物对早期脓毒症急性呼吸窘迫综合征患者血小板活化及血小板-白细胞聚集体形成的影响
BMC Pharmacol Toxicol. 2025 Jan 6;26(1):4. doi: 10.1186/s40360-024-00806-x.
2
Atorvastatin Effect on COVID-19 Outcomes: A Propensity Score Matched Study on Hospitalized Patients.阿托伐他汀对新冠病毒病结局的影响：一项针对住院患者的倾向评分匹配研究。
Curr Med Chem. 2024 Jan 21. doi: 10.2174/0109298673264305231025093939.
3
Old drugs, new tricks: leveraging known compounds to disrupt coronavirus-induced cytokine storm.老药新用：利用已知化合物来阻断冠状病毒引起的细胞因子风暴。
NPJ Syst Biol Appl. 2022 Oct 10;8(1):38. doi: 10.1038/s41540-022-00250-9.
4
Multiplex Testing of the Effect of Statins on Disease Severity Risk in COVID-19 Cases.他汀类药物对 COVID-19 病例疾病严重程度风险的多重检测。
Methods Mol Biol. 2022;2511:273-284. doi: 10.1007/978-1-0716-2395-4_20.
5
RBC-hitchhiking chitosan nanoparticles loading methylprednisolone for lung-targeting delivery.载甲泼尼龙红细胞搭便车壳聚糖纳米粒用于肺部靶向递药。
J Control Release. 2022 Jan;341:702-715. doi: 10.1016/j.jconrel.2021.12.018. Epub 2021 Dec 18.
6
HMG-CoA reductase inhibitors and COVID-19 mortality in Stockholm, Sweden: A registry-based cohort study.羟甲基戊二酰辅酶 A 还原酶抑制剂与瑞典斯德哥尔摩地区 COVID-19 死亡率：一项基于登记的队列研究。
PLoS Med. 2021 Oct 14;18(10):e1003820. doi: 10.1371/journal.pmed.1003820. eCollection 2021 Oct.
7
Direct Activation of Endothelial Cells by SARS-CoV-2 Nucleocapsid Protein Is Blocked by Simvastatin.辛伐他汀可阻断 SARS-CoV-2 核衣壳蛋白对血管内皮细胞的直接激活。
J Virol. 2021 Nov 9;95(23):e0139621. doi: 10.1128/JVI.01396-21. Epub 2021 Sep 22.
8
Statins in COVID-19 Therapy.他汀类药物用于新冠病毒病治疗
Life (Basel). 2021 Jun 16;11(6):565. doi: 10.3390/life11060565.
9
Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis.他汀类药物治疗后改善新型冠状病毒肺炎重症监护病房收治情况及死亡率：一项系统评价和荟萃分析
Arch Med Sci. 2021 Feb 10;17(3):579-595. doi: 10.5114/aoms/132950. eCollection 2021.
10
The Novel Coronavirus and Inflammation.新型冠状病毒与炎症。
Adv Exp Med Biol. 2021;1321:127-138. doi: 10.1007/978-3-030-59261-5_11.

本文引用的文献

1
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.113 例新冠肺炎死亡患者的临床特征：回顾性研究。
BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091.
2
Intravenous Statin Administration During Myocardial Infarction Compared With Oral Post-Infarct Administration.心肌梗死后静脉给予他汀类药物与口服给药的比较。
J Am Coll Cardiol. 2020 Mar 31;75(12):1386-1402. doi: 10.1016/j.jacc.2020.01.042.
3
Treatment for severe acute respiratory distress syndrome from COVID-19.新型冠状病毒肺炎所致严重急性呼吸窘迫综合征的治疗
Lancet Respir Med. 2020 May;8(5):433-434. doi: 10.1016/S2213-2600(20)30127-2. Epub 2020 Mar 20.
4
Exuberant Plasmocytosis in Bronchoalveolar Lavage Specimen of the First Patient Requiring Extracorporeal Membrane Oxygenation for SARS-CoV-2 in Europe.欧洲首例因新型冠状病毒肺炎需体外膜肺氧合治疗患者的支气管肺泡灌洗标本中出现的旺盛浆细胞增多症
J Thorac Oncol. 2020 May;15(5):e65-e66. doi: 10.1016/j.jtho.2020.03.008. Epub 2020 Mar 17.
5
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
6
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2.全长人血管紧张素转化酶 2 识别 SARS-CoV-2 的结构基础。
Science. 2020 Mar 27;367(6485):1444-1448. doi: 10.1126/science.abb2762. Epub 2020 Mar 4.
7
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局：一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
8
Statins: Complex outcomes but increasingly helpful treatment options for patients.他汀类药物：复杂的结局，但对患者来说是越来越有帮助的治疗选择。
Eur J Pharmacol. 2019 Nov 15;863:172704. doi: 10.1016/j.ejphar.2019.172704. Epub 2019 Sep 27.
9
Increase in circulating ACE-positive endothelial microparticles during acute lung injury.急性肺损伤时循环 ACE 阳性内皮微颗粒增加。
Eur Respir J. 2019 Oct 17;54(4). doi: 10.1183/13993003.01188-2018. Print 2019 Oct.
10
Phenotypes in acute respiratory distress syndrome: moving towards precision medicine.急性呼吸窘迫综合征的表型：迈向精准医学。
Curr Opin Crit Care. 2019 Feb;25(1):12-20. doi: 10.1097/MCC.0000000000000571.